GALVANI BIOELECTRONICS LIMITED

Active Stevenage
22 employees website.com
Life sciences and medical technology
G

GALVANI BIOELECTRONICS LIMITED

Founded 3 Feb 2016 Active Stevenage, United Kingdom 22 employees website.com
Life sciences and medical technology

Previous Company Names

GSK BIOELECTRONICS (NO.1) LIMITED 3 Feb 2016 — 29 Apr 2016
Accounts Submitted 9 Jun 2025 Next due 30 Sept 2026 3 months remaining
Confirmation Submitted 23 Jul 2025 Next due 6 Aug 2026 1 month remaining
Net assets £97M £4M 2024 year on year
Total assets £104M £3M 2024 year on year
Total Liabilities £7M £502K 2024 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

Gsk Medicines Research Centre Gunnels Wood Road Stevenage SG1 2NY United Kingdom

Website

www.example.com

Full company profile for GALVANI BIOELECTRONICS LIMITED (09984862), an active life sciences and medical technology company based in Stevenage, United Kingdom. Incorporated 3 Feb 2016. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type full
Next accounts 31 Dec 2025
Due by 30 Sept 2026 3 months remaining

Net Assets, Total Assets & Total Liabilities (2016–2024)

Cash in Bank

N/A

Net Assets

£97.08M

Increased by £3.69M (+4%)

Total Liabilities

£7.09M

Decreased by £502.00k (-7%)

Turnover

N/A

Employees

22

Decreased by 1 (-4%)

Debt Ratio

7%

Decreased by 1 (-13%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
31 Dec Year End
2023
31 Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 1

Investors (2)

Investor NameInvestor SinceParticipating Rounds
Investor 1Aug 2016Strategic Investment
Investor 2Aug 2016Strategic Investment

Share Capital

Share Capital

Share allotments and capital structure

17 Allotments 4,011 Shares £157.68m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
15 Apr 2026275£2.92m£11k
15 Apr 2026180£1.91m£11k
15 Apr 202645£477k£11k
30 Sept 2024275£9.35m£34k
30 Sept 2024225£7.65m£34k

Officers

Officers

1 active 2 resigned
Status
Anurag MehtaDirectorAmericanUnited States4816 Jun 2023Active

Shareholders

Shareholders (3)

Setfirst Limited
55.0%
Verily Life Sciences Llc
36.0%

Persons with Significant Control

Persons with Significant Control (2)

2 Active

Setfirst Limited

United Kingdom

Active
Notified 6 Apr 2016
Nature of Control
  • Ownership Of Shares 50 To 75 Percent,voting Rights 50 To 75 Percent,right To Appoint And Remove Directors

Alphabet Inc.

United States Of America

Active
Notified 16 Nov 2016
Nature of Control
  • Ownership Of Shares 25 To 50 Percent,voting Rights 25 To 50 Percent,right To Appoint And Remove Directors

Group Structure

Group Structure

GSK PLC united kingdom
SETFIRST LIMITED united kingdom
GALVANI BIOELECTRONICS LIMITED Current Company

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
15 May 2026ResolutionResolutions
7 May 2026OfficersTermination of Andrew Trister as director on 1 May 2026
27 Apr 2026CapitalAllotment of shares (GBP 6,000) on 15 Apr 2026
27 Mar 2026OfficersTermination of Theresa Podrebarac as director on 23 Mar 2026
9 Oct 2025OfficersAppointment of Mr Calvin Courtland as director on 29 Sept 2025
15 May 2026 Resolution

Resolutions

7 May 2026 Officers

Termination of Andrew Trister as director on 1 May 2026

27 Apr 2026 Capital

Allotment of shares (GBP 6,000) on 15 Apr 2026

27 Mar 2026 Officers

Termination of Theresa Podrebarac as director on 23 Mar 2026

9 Oct 2025 Officers

Appointment of Mr Calvin Courtland as director on 29 Sept 2025

Recent Activity

Latest Activity

Resolutions

3 weeks ago on 15 May 2026

Termination of Andrew Trister as director on 1 May 2026

1 months ago on 7 May 2026

Allotment of shares (GBP 6,000) on 15 Apr 2026

1 months ago on 27 Apr 2026

Termination of Theresa Podrebarac as director on 23 Mar 2026

2 months ago on 27 Mar 2026

Appointment of Mr Calvin Courtland as director on 29 Sept 2025

8 months ago on 9 Oct 2025